Overview


According to FutureWise analysis the market for allergy immunotherapy in 2023 is US$ 2.28 billion, and is expected to reach US$ 4.61 billion by 2031 at a CAGR of 9.20%.

A medical procedure designed to lessen or eliminate allergy symptoms is allergy immunotherapy, sometimes referred to as allergy shots. It is a type of immunotherapy that entails gradually exposing a patient to small quantities of an allergen, for example, pet dander or pollen. The purpose of allergy immunotherapy is to assist the patient's immune system develop tolerance to the allergen. This is accomplished by gradually raising the allergen's dosage over time, which aids in the immune system's ability to recognize the allergen as harmless and quit mounting an allergic reaction. Hay fever, allergic asthma, and reactions caused by bee stings are frequently treated with allergy immunotherapy. It is frequently recommended for people who do not respond to or cannot tolerate traditional allergy therapies such as antihistamines or nasal corticosteroids.

There are two main types of allergy immunotherapy administration: subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). SCIT involves injecting small amounts of allergens under the skin, usually in the upper arm. The injections are generally given on a regular schedule, starting with a very small dose that is gradually increased over time. SCIT is typically given in a doctor's office and requires close monitoring for potential side effects. SLIT involves placing small amounts of allergen extract under the tongue. Like SCIT, the treatment is usually given regularly, and the dose is gradually increased over time. SLIT is typically done at home and doesn't require as much monitoring as SCIT, but it may not be as effective as SCIT for some types of allergies. There is also a newer type of allergy immunotherapy administration called epicutaneous immunotherapy (EPIT), which involves placing a patch containing an allergen extract on the skin. 

FutureWise Market Research has published a report that provides an insightful analysis of Allergy Immunotherapy Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that Allergy Immunotherapy Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • ASIT Biotech
  • Circassia
  • Mylan N.V
  • Adamis Pharmaceuticals Corporation
  • Merck KGaA
  • Stallergenes Greer plc
  • Allergy Therapeutics
  • Hollisterstier Allergy
  • Leti pharma
  • DBV Technologies SA

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Allergy Immunotherapy Market:

  • According to a press release from Aravax Pty Ltd, Phase 2 clinical trials for PVX108, a cutting-edge immunotherapy for treating peanut allergy, started in March 2022.

Allergy immunotherapy is a treatment method for allergies that involves exposing the patient to increasing allergen dosages progressively over time. This assists the body in developing tolerance to the allergen, reducing the severity of symptoms and the risk of anaphylaxis. Allergy immunotherapy can be administered in different forms, such as subcutaneous injections, sublingual drops or tablets, and intranasal sprays. The allergy immunotherapy market is driven by numerous factors, including the increasing prevalence of allergies. With the rise in air pollution, exposure to chemicals, and changing lifestyles, allergies are becoming more common, driving the demand for effective treatments. In addition to the increasing prevalence of allergies, technological advancements are also influencing the growth of the allergy immunotherapy market. For example, developing new formulations, such as sublingual tablets and drops, has made allergy immunotherapy more convenient and less invasive for patients. There have also been advancements in the delivery methods of allergy immunotherapy, such as using autoinjectors and prefilled syringes, which have improved the ease and safety of administration. Another factor driving the growth of the allergy immunotherapy market is the increasing awareness of the benefits of this treatment method among healthcare professionals and patients. As more studies are conducted, and data is collected, the efficacy of allergy immunotherapy is becoming more widely recognized, leading to greater demand for this treatment.

Despite these positive trends, there are also various challenges facing the allergy immunotherapy market. The major challenge associated with the allergy immunotherapy market is the cost of treatment, which can be a barrier to access for some patients. Additionally, the regulatory environment for allergy immunotherapy can vary from country to country, creating challenges for manufacturers seeking to bring their products to market.

By Treatment Type

  • Subcutaneous Immunotherapy
  • Sublingual Immunotherapy
    • Tablets
    • Drops

By Allergy Type

  • Allergic Rhinitis
  • Allergic Asthma
  • Others

By End User

  • Hospital
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. Europe registered the highest share in the market in 2022. A large population with a variety of allergies is considered to be a contributing factor to the region's dominance. According to the European Academy of Allergy and Clinical Immunology, more than 150 million chronic food allergy sufferers are in the region, or 20% of the total population. Asthma and allergic rhinitis are widespread allergies, affecting 70 million and 100 million individuals, respectively. In addition, according to the organization, by 2025, 50 percent of the population in Europe may have allergies, opening up a huge market for allergy immunotherapy. The frequency of allergies in Europe is also becoming a significant economic burden owing to reduced productivity in European nations. As a result of these issues, European governments and organizations, including EAACI, are attempting to raise public awareness. They are advocating for better medical care and education, which will help the market in the region flourish. Additionally, based on allergy type; the allergic rhinitis segment holds the highest market share of 71.6% in 2022.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Allergy Immunotherapy market By Treatment Type, By Allergy Type, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record and evaluate the competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Allergy Immunotherapy Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Global Allergy Immunotherapy Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Allergy Immunotherapy Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Allergy Immunotherapy Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Allergy Immunotherapy Market, By Treatment Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Subcutaneous Immunotherapy
        2. Sublingual Immunotherapy
         2.1. Tablets
         2.2. Drops

  • 8.   Global Allergy Immunotherapy Market, By Allergy Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Allergic Rhinitis
        2. Allergic Asthma
        3. Others

  • 9.   Global Allergy Immunotherapy Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital
        2. Retail Pharmacy
        3. Online Pharmacy

  • 10.   North America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Regional Market Trends
        3. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         3.1. Brazil
         3.2. Venezuela
         3.3. Argentina
         3.4. Rest of Latin America
        4. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Switzerland
         2.9. Rest of Western Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. India
         2.5. Australia and New Zealand
         2.6. ASEAN
         2.7. South Korea
         2.8. Taiwan
         2.9. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.  Market Share Analysis and Competitive Landscape
    •      1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
    •   1. ASIT Biotech
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Circassia
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Mylan N.V.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Adamis Pharmaceuticals Corporation
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Merck KGaA
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Stallergenes Greer plc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Allergy Therapeutics
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. HollisterStier Allergy
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Leti pharma
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. DBV Technologies SA
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nation
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients